BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 04, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Locteron: Additional Phase IIb data

Additional data from the international Phase IIb SELECT-2 trial in 116 treatment-naïve HCV patients showed that 320, 480 and 640 µg subcutaneous Locteron every other week led to lower increases in peak mean BDI scores from baseline vs. 1.5 µg/kg PegIntron peginterferon alfa-2b (67%, 30% and...

Read the full 220 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >